We observed that cyclin-dependent kinase inhibitor gene CDKN2A rs3088440 was significantly related with a poorer treatment efficacy on the primary tumor and cervical lymph node after radiotherapy, and also with a decreased risk of grade 3–4 acute radiation-induced myelosuppression. Here, CDKN2A is linked to neoplasm.